Takeda to move US headquarters in Deerfield to Massachusetts

Takeda on Tuesday ​said​ that it plans to close its US office in Deerfield, Illinois​, which employs just under 1000 employees,​ and ​move to the Boston area. Takeda spokeswoman Julia Ellwanger commented "this move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success," adding "it will also simplify our existing Takeda US operations."  

Ellwanger explained that the work performed at Takeda's Illinois site will be progressively transferred to Massachusetts after the drugmaker completes its planned takeover of Shire early next year. The spokeswoman noted that while the date of closure of the site is unclear, employees will be informed of their personal outcomes within six months after the Shire transaction is completed.

"If the Shire deal does not close, it would remain our intent to progressively consolidate from Deerfield into the greater Boston area," Ellwanger stated​, adding that "the Deerfield closure will impact all employees who physically work out of the Deerfield site​. It does not apply to field-based roles​.​ " ​The spokeswoman ​further indicated that some employees at the Illinois site will be offered jobs in other locations without providing specifics.  

Last year, sources reported that as many as 600 people in the drugmaker's R&D unit and 150 people in the vaccines operation have been shifted from Illinois to Massachusetts.​

​Takeda has ​previously estimated that​, by the third year, it expects cost savings of $1.4 billion associated with the ​Shire acquisition​, including savings of about $600 million in ​duplicated ​R&D ​costs, as well as a workforce reduction of 6 percent to 7 percent. Shortly after the agreement was announced, Takeda CEO Christophe Weber stated that the company will carefully pursue the large spending cuts needed to make the acquisition viable.  

Meanwhile, the news comes after the US Federal Trade Commission granted unconditional clearance of Takeda's planned acquisition of Shire. Although some investors have criticised the acquisition, the group failed to win support for a measure that would have ​required Takeda to receive advance​ shareholder approval for large deals. 

For related analysis on the Takeda-Shire deal, see ViewPoints: Shire shows signs of pulling its weight for Takeda

To read more Top Story articles, click here.